Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE: Osimertinib Plus Chemotherapy in EGFRm NSCLC With Distant Recurrence After Adjuvant Osimertinib
NCT07279935Phase 4Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started May 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07279935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279935.